Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sjögren's Syndrome
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
AMASS is a double-blinded randomized clinical trial with the purpose of investigating whether
injection of allogeneic adipose-derived mesenchymal stem cells (ASCs) into the lacrimal gland
(LG) results in increased ocular comfort compared to placebo.